Other possible mechanisms are as follows: inhibition of nuclear factor κB (NF-κB) and induction of apoptosis by modulation of activity of TNF-α and NF-κB. In a double-blind placebo-controlled trial (n = 62) in patients with stable coronary artery disease, following administration of 1 mg/kg subcutaneous enoxaparin, plasma levels of myeloperoxidase (MPO) increased significantly (P < 0.001) and subsequently endothelial function improved (r = 0.67, P < 0.001) through MPO binding to endothelium and depleting vascular nitric oxide [57]. Here, MPO is linked to coronary artery disorder.